［1］Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2018，68(6)：394-424.
［2］Chen WQ，Zheng RS，Baade PD，et al.Cancer statistics in China，2015［J］.CA：A Cancer Journal for Clinicians，2016，66(2)：115-132.
［3］LI YX，WANG LH，GAO L，et al.Radiation oncology(version5)［M］.Beijing：Peking Union Medical College Press，2018：1068.［李晔雄，王绿化，高黎，等.肿瘤放射治疗学（第五版）［M］.北京：中国协和医科大学出版社，2018：1068.］
［4］Smith BD，Smith GL，Haffty BG.Postmastectomy radiation and mortality in women with T1-2 node-positive breast cancer［J］.J Clin Oncol，2005，23(7)：1409-1419.
［5］Ragaz J，Olivotto IA，Spinelli JJ，et al.Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy：20-year results of the British Columbia randomized trial［J］.Journal of the National Cancer Institute，2005，97(2)：116-126.
［6］Overgaard M，Nielsen HM，Overgaard J.Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes，as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials［J］.Radiotherapy and Oncology，2007，82(3)：247-253.
［7］HAO JL，XU LM，GAO QL，et al.Value of postmastectomy radiotherapy in T2 breast cancer patients with 1-3 positive axillary lymph nodes［J］.Chin J Clin Oncol，2010，37(02)：113-116.［郝建磊，徐利明，高秋玲，等.术后放疗在伴有腋窝淋巴结1～3枚阳性T2期乳腺癌中的作用［J］.中国肿瘤临床，2010，37(02)：113-116.］
［8］WANG SL，YU ZH，LI YX，et al.The role of postmastectomy radiotherapy in breast cancer patients with T1-T2 and one to three positive axillary nodes［J］.Chinese Journal of Radiation Oncology，2009，18(4)：291-294.［王淑莲，余子豪，李晔雄，等.T1-T2期伴1-3个腋窝淋巴结转移乳腺癌患者改良根治术后放疗的作用［J］.中华放射肿瘤学杂志，2009，18(4)：291-294.］
［9］Tam M，Wu SP，Perez C，et al.The effect of post-mastectomy radiation in women with one to three positive nodes enrolled on the control arm of BCIRG-005 at ten year follow-up［J］.Radiotherapy and Oncology，2017，123(1)：10-14.
［10］Muhsen S，Moo T，Patil S，et al.Most breast cancer patients with T1-2 tumors and one to three positive lymph nodes do not need postmastectomy radiotherapy［J］.Ann Sur Oncol，2018，25(7)：1912-1920.
［11］Chang JS，Lee J，Kim KH，et al.Do recent advances in diagnostic and therapeutic procedures negate the benefit of postmastectomy radiotherapy in N1 patients with a low risk of locoregional recurrence［J］?Medicine (Baltimore)，2015，94(33)：e1259.
［12］Lai S，Chen Y，Kuo W，et al.Locoregional recurrence risk for postmastectomy breast cancer patients with T1-2 and one to three positive lymph nodes receiving modern systemic treatment without radiotherapy［J］.Ann Surg Oncol，2016，23(12)：3860-3869.
［13］Huo D，Hou N，Jaskowiak N，et al.Use of postmastectomy radiotherapy and survival rates for breast cancer patients with T1-T2 and one to three positive lymph nodes［J］.Ann Surg Oncol，2015，22(13)：4295-4304.
［14］Chen D，Wang H，Song X，et al.A prognostic score model to determine which breast cancer patients with 1-3 positive lymph nodes after modified radical mastectomy should receive radiotherapy［J］.Oncotarget，2018，9(1)：385.
［15］Niu S，Wen G，Ren Y，et al.Predictive value of primary tumor site for loco-regional recurrence in early breast cancer patients with one to three positive axillary lymphadenophy［J］.Journal of Cancer，2017，8(12)：2394-2400.
［16］Rakha EA，Morgan D，Macmillan D.The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma：Number or stage［J］.J Clin Pathol，2012，65(7)：624-630.
［17］Kim SI，Cho S，Lee JS，et al.Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes［J］.British Journal of Cancer，2013，109(5)：1165-1171.
［18］Truong PT，Olivotto IA，Kader HA，et al.Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy［J］.Int J Radiat Oncol Biol Phys，2005，61(5)：1337-1347.
［19］DAI MM，WU SG，HE ZY，et al.Prognostic value of Ki -67 in axillary lymph node-positive breast cancer after mastectomy［J］.Modern Oncology，2013，21(07)：1503-1507.［戴明明，吴三纲，何振宇，等.Ki-67对腋窝淋巴结阳性的乳腺癌全乳腺切除术后的预后价值［J］.现代肿瘤医学，2013，21(07)：1503-1507.］
［20］Cheng JC，Chen CM，Liu MC，et al.Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy［J］.Int J Radiat Oncol Biol Phys，2002，52(4)：980-988.
［21］Fodor J，Polgar C，Major T，et al.Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size［J］.Strahlenther Onkol，2003，179(3)：197-202.
［22］Obedian E，Haffty B.Internal mammary nodal irradiation in conservatively-managed breast cancer patients：Is there a benefi［J］?Int J Radiat Oncol Biol Phys，1999，5(44)：997-1003.
［23］Poortmans PM，Collette S，Kirkove C，et al.Internal mammary and medial supraclavicular irradiation in breast cancer［J］.N Engl J Med，2015，373(4)：317-327.
［24］Whelan TJ，Olivotto IA，Parulekar WR，et al.Regional nodal irradiation in early-stage breast cancer［J］.N Engl J Med，2015，373(4)：307-316.
［25］Whelan TJ，Olivotto IA，Levine MN.Regional nodal irradiation in early-stage breast cancer［J］.N Engl J Med，2015，373(19)：1878-1879.
［26］Mcgale P，Taylor C，Correa C，et al.Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality：Meta-analysis of individual patient data for 8135 women in 22 randomised trials［J］.Lancet，2014，383(9935)：2127-2135.
［27］Recht A，Comen EA，Fine RE，et al.Postmastectomy radiotherapy：an American society of clinical oncology，American society for radiation oncology，and society of surgical oncology focused guideline update［J］.J Clin Oncol，2016，34(36)：4431-4442.
［28］Kirova YM，Carroll S，Fourquet A，et al.The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017：The point of view of an International Panel of Experts in Radiation Oncology［J］.Ann Oncol，2018，29(1)：280-281.
［29］NCCN.NCCN clinical practice guidelines in oncology：Breast cancer［EB/OL］.［2018-03-20］.http：//www.NCCN.org/patients.pdf.
［30］Southwest Oncology Group (SWOG).Randomized trial of post-mastectomy radiotherapy in stage II breast cancer in women with one to three positive axillary nodes，phase III (SWOG 9927)［EB/OL］.2013.http：//www.swog.org/clinicaltrials.